Scleroderma Treatment

What Is Scleroderma?

Scleroderma is a chronic autoimmune connective tissue disease in which the immune system triggers inflammation, narrows small blood vessels and prompts the body to produce too much collagen. The name means “hard skin”, and thickened, tightened skin is the condition’s most recognisable feature — but the disease reaches further than the skin. When internal organs are involved, doctors use the term systemic sclerosis; you will sometimes see the two names written together as systemic sclerosis/systemic scleroderma, because they describe the same condition from two angles: what it does to the skin, and what it can do inside the body.

A brief note on spelling. Some people type “squaderma” when they first search for information. There is no separate condition by that name — it is simply a common misspelling of scleroderma, and everything on this page applies.

Being told you may have scleroderma is unsettling, in part because the condition is not confined to one organ or one symptom. Some people first notice tight skin on the fingers, colour changes in the hands when exposed to cold, joint stiffness, reflux, fatigue or shortness of breath. Others are diagnosed only after blood tests or imaging suggest that the immune system is affecting the connective tissue that supports the skin, blood vessels, lungs, digestive tract, kidneys or heart.

Scleroderma also behaves very differently from one person to the next. For some, changes stay mostly in the skin and progress slowly over years. For others, internal organ involvement develops and needs close monitoring and timely treatment. This variability is one reason people often seek a second opinion or care at a centre with genuine experience in complex autoimmune disease: the same diagnosis can mean two very different care plans.

Treatment matters because scleroderma can affect comfort, mobility, breathing, digestion, circulation and long-term organ function. No current treatment reverses the disease completely for every patient, and it is important to say that plainly. What modern care can do is control symptoms, slow certain complications, protect organs and support daily life. The goal is not only to treat what is visible on the skin, but to detect what may be developing silently inside the body — and to respond early rather than late.

What Causes Scleroderma?

The precise cause of scleroderma is not known. What is well understood is that three processes interact: an overactive immune response, injury to the lining of small blood vessels, and overactivity of fibroblasts — the cells that manufacture collagen. Together these produce inflammation, reduced blood flow and a gradual stiffening of connective tissue in the skin and, in systemic disease, in internal organs.

Research points to a combination of genetic susceptibility and environmental exposure rather than a single trigger. Certain occupational exposures, such as silica dust and some solvents, have been associated with the disease in a proportion of patients, which is why your doctor will ask about your work history. Scleroderma is more common in women and typically appears in early to mid adulthood, though it can begin at any age, including in childhood. It is not contagious, and it is not caused by anything you did or failed to do.

Is scleroderma hereditary?

Scleroderma is not inherited in a simple, predictable pattern, and most people who develop it have no affected relatives. Genes appear to contribute susceptibility rather than certainty: autoimmune conditions of various kinds can cluster loosely in families, so a relative might have a thyroid disorder or another connective tissue disease rather than scleroderma itself. A family history of autoimmune illness is worth mentioning at your evaluation because it adds context, but a diagnosis in a parent does not mean their children will develop the disease, and genetic testing is not part of routine diagnosis.

Types of Scleroderma

Scleroderma is divided into localised and systemic forms, and the distinction matters because monitoring and treatment differ substantially between them. Getting the classification right is one of the most useful things a first specialist assessment can do for you.

Localised scleroderma: morphea and linear disease

Localised scleroderma, sometimes called morphea or linear scleroderma, affects the skin and the tissues directly beneath it without the pattern of internal organ disease seen in systemic sclerosis. Morphea appears as firm, discoloured patches or plaques; linear scleroderma forms bands of thickened skin, often on a limb or the face. It is the form most often seen in children. Treatment focuses on controlling skin inflammation, preventing contractures, and protecting growth and function when lesions cross joints or occur during childhood. People with localised disease still deserve proper follow-up, but the surveillance plan is different from the one used for systemic disease.

Systemic sclerosis: limited and diffuse forms

Systemic sclerosis is the form of scleroderma that can involve internal organs alongside the skin, and it is itself divided into two broad patterns. In limited cutaneous systemic sclerosis, skin involvement stays mainly on the hands, forearms, feet, lower legs, face or neck; the skin course tends to be slower, but pulmonary hypertension can develop over time, so long-term heart and lung screening remains important. In diffuse cutaneous systemic sclerosis, skin thickening is more widespread and internal organ involvement — particularly of the lungs and kidneys — can appear earlier, which calls for more intensive surveillance in the first years. These categories guide monitoring, but they are starting points: every patient still needs individual assessment, because the disease does not always follow the textbook.

What is CREST syndrome?

CREST syndrome is an older name for what is now usually called limited cutaneous systemic sclerosis. The letters stand for calcinosis (calcium deposits under the skin), Raynaud’s phenomenon, oesophageal dysmotility, sclerodactyly (tight skin over the fingers) and telangiectasia (visible clusters of small blood vessels). You will still see the term in older reports and online, and the five features remain a useful checklist. Two cautions apply. First, not everyone with limited disease has all five features. Second, carrying the CREST label does not rule out internal organ involvement — screening of the lungs and heart still applies.

Is scleroderma the same as other conditions called “sclerosis”?

No. The word sclerosis simply means hardening, and it appears in the names of several unrelated diseases. Multiple sclerosis, for example, affects the nervous system and has nothing to do with scleroderma beyond the shared root word. Closer to home, scleroderma can overlap with — or initially be mistaken for — other autoimmune connective tissue diseases such as systemic lupus erythematosus and Sjögren’s syndrome, and some patients genuinely have features of more than one condition at the same time. Distinguishing between these possibilities, or recognising an overlap, is a large part of why specialist assessment matters at the start.

Scleroderma Symptoms

Scleroderma symptoms depend on the type of disease, the organs involved and how active the condition is at a given time. Some symptoms are visible and obvious; others develop quietly inside the body and are found only through testing. Both kinds matter, and a good evaluation looks for both.

What are the first signs of scleroderma?

For many people, the first sign is Raynaud’s phenomenon — fingers or toes turning white, blue or red in response to cold or emotional stress. Raynaud’s is common in the general population and is often harmless on its own. It becomes more significant when it appears alongside puffy or swollen fingers, skin that is beginning to thicken or shine, abnormal autoimmune blood tests, sores at the fingertips, or visible changes in the tiny blood vessels at the base of the fingernails. Other early clues include heartburn, difficulty swallowing, unexplained fatigue and joint stiffness — none of them specific by themselves, but meaningful in combination.

As the disease establishes itself, symptoms can appear across several systems:

• Skin: thickened, tight or shiny skin; itching; reduced ability to bend the fingers; calcium deposits under the skin; small visible blood vessels on the face or hands; a gradually reduced mouth opening.
• Circulation: Raynaud’s attacks, painful sores or ulcers at the fingertips, and slow healing of small wounds on the hands and feet.
• Joints and muscles: joint pain and stiffness, tendon friction that can be felt or heard on movement, and muscle weakness or aching.
• Digestive system: heartburn and reflux, difficulty swallowing, bloating, constipation, diarrhoea, delayed stomach emptying, small intestinal bacterial overgrowth and unintended weight loss.
• Lungs: a dry cough or breathlessness with activity, which can signal interstitial lung disease or pulmonary hypertension — sometimes before either feels dramatic.
• Heart: palpitations, rhythm disturbances or, less commonly, involvement of the heart muscle or its lining.
• Kidneys: rising blood pressure and changes in kidney function, which in a small group of patients can develop quickly as scleroderma renal crisis.

Two practical points deserve emphasis. First, fatigue is real in scleroderma and is not a character flaw; it reflects the disease and sometimes its complications. Second, mouth and dental health can be affected when mouth opening narrows and saliva decreases, making chewing and oral hygiene harder — one of the reasons dental care features in scleroderma management, as explained in our page on oral health and systemic diseases.

Who May Need Scleroderma Evaluation and Treatment

Evaluation is worth considering when symptoms suggest autoimmune connective tissue disease, especially when several occur together. The pattern matters more than any single finding: Raynaud’s plus puffy fingers is a different picture from Raynaud’s alone, and skin thickening plus breathlessness is a different picture again.

People who already carry a scleroderma diagnosis may also need renewed assessment when circumstances change: symptoms are progressing, current medication is poorly tolerated, new organ findings have appeared on tests, or a more complete evaluation is wanted before starting or changing therapy. Many patients want three specific things from a renewed assessment — confirmation of the subtype, a clear treatment roadmap, and coordinated input from multiple specialties gathered in one place rather than pieced together over months.

It is also worth saying what evaluation is not. It is not a commitment to aggressive treatment. Many patients leave a thorough assessment with a monitoring plan and modest, targeted therapy — and the reassurance of knowing exactly what has and has not been found.

How Is Scleroderma Diagnosed?

Scleroderma is diagnosed through a combination of clinical examination, blood tests and organ-specific investigations — there is no single test that settles it alone. A rheumatologist begins with a detailed history and physical examination, looking at the pattern of skin involvement, vascular changes, joint and tendon findings, and clues to internal organ involvement. Disease duration, family history, occupational exposures, current medications, pregnancy considerations where relevant, prior infections and other autoimmune conditions all feed into the picture.

Blood tests usually include antinuclear antibodies and more specific scleroderma-associated antibodies, such as anti-centromere and anti-topoisomerase antibodies. These do not tell the whole story by themselves — people can carry antibodies without disease, and occasionally the reverse — but they help clarify the subtype and calibrate how intensively the organs should be watched.

Modern diagnostic pathways then add targeted tests as needed: nailfold capillaroscopy to examine the small blood vessels near the fingernails; pulmonary function tests to measure breathing capacity and gas transfer; high-resolution chest imaging when lung involvement is suspected; echocardiography to screen for pulmonary hypertension or heart strain; electrocardiography when rhythm symptoms are present; kidney function tests, urine analysis and blood pressure monitoring; and gastrointestinal evaluation — endoscopy, swallowing studies, motility testing or breath testing — when reflux or bowel symptoms need explanation. The purpose of all of this is to understand the whole disease profile, not simply to attach a label.

How Is Scleroderma Treated, Step by Step

Scleroderma treatment is a long-term management plan rather than a single procedure. It is usually directed by a rheumatologist, with other specialists brought in as organ involvement requires. In practical terms, care runs through four connected stages:

• Step 1 — Confirm the diagnosis and classify the disease as localised or systemic, limited or diffuse.
• Step 2 — Map organ involvement with baseline tests of the lungs, heart, kidneys, circulation and digestive system.
• Step 3 — Select targeted treatments matched to the problems that are actually present, introduced in a deliberate order.
• Step 4 — Monitor on a schedule so that changes are caught early, rather than after complications have advanced.

Initial assessment and preparation

Treatment begins with a comprehensive assessment. It helps to arrive with previous test results, imaging studies, biopsy reports if any exist, a current medication list, and notes from earlier rheumatology, pulmonology, cardiology, nephrology, dermatology or gastroenterology consultations. Well-organised, summarised records make the first visit considerably more efficient.

The preparation phase includes baseline testing. Blood tests evaluate inflammation, immune markers, kidney and liver function, blood counts, muscle enzymes and safety parameters for potential medications. Urine tests and blood pressure monitoring matter because kidney involvement can develop quickly in certain patients. Lung, heart and gastrointestinal evaluation are added according to symptoms and subtype, as described in the diagnosis section above.

Building the treatment plan

Once the disease pattern is understood, the care team defines the main priorities. For one patient that may be controlling Raynaud’s attacks and preventing fingertip ulcers; for another, treating interstitial lung disease, calming active skin thickening, or improving reflux and nutrition. Treatment is usually staged rather than started all at once, so that response and side effects can be judged honestly.

Medication plans may include vasodilators for circulation problems; vascular protection strategies in selected cases; acid-suppression treatment for reflux; prokinetic medication for motility problems; antibiotics for bacterial overgrowth when appropriate; immune-modulating medication for active skin or lung disease; and therapies directed at pulmonary hypertension if it is present. In scleroderma renal crisis, rapid recognition and specific blood pressure treatment are essential — one of the clearest examples of why monitoring is built into the plan. For carefully selected patients with severe, rapidly progressive disease, advanced therapies may be discussed by experienced specialists after weighing benefits against risks; these decisions belong to the treating team and are never taken lightly. Whatever the plan, any change to medication is made by your treating doctor.

Non-medication care carries real weight. Patients receive guidance on cold protection, smoking avoidance, skin and wound care, hand exercises and stretching, nutrition, swallowing safety, dental care where mouth opening is reduced, and safe physical activity. Occupational therapy can add hand splints, adaptive tools and practical strategies for preserving independence. Pulmonary rehabilitation may help selected patients with lung involvement.

The technology used in scleroderma care

Technology in scleroderma care serves precision: in diagnosis, organ surveillance and treatment monitoring. Nailfold capillaroscopy shows the small-vessel changes associated with systemic disease. Pulmonary function testing measures lung volume and gas transfer, identifying early interstitial changes or drift over time. High-resolution chest imaging reveals patterns of lung scarring that a standard chest X-ray can miss. Echocardiography screens for pulmonary hypertension and heart function changes; electrocardiography and rhythm monitoring are used when palpitations or fainting raise concern. Endoscopic and motility tests clarify the cause of swallowing difficulty, reflux or intestinal symptoms, and laboratory platforms support antibody testing and medication safety checks. The value of all this equipment lies not in the machines themselves, but in how the results are read together by specialists who understand the disease.

How long does treatment take?

There is no single “procedure time” for scleroderma because treatment is ongoing. The first diagnostic evaluation may take several visits, or a coordinated assessment concentrated into a short period, depending on the complexity of the case. Starting a new medication involves baseline screening, education about possible side effects and follow-up blood tests. Some symptoms respond over weeks; organ-directed treatment is judged over months, with repeat testing. During active disease or medication changes, follow-up typically happens every few months, spacing out when the condition is stable. Lung, heart, kidney and blood pressure checks are repeated at intervals set by the subtype and risk profile. A consolidated evaluation can conclude with a written care plan that other physicians involved in your care can use to continue monitoring between visits.

What does recovery look like in daily life?

Because scleroderma is chronic, recovery is best understood as stabilisation, symptom improvement, prevention of complications and preservation of function — not disappearance of the disease. Some gains come quickly: reflux, Raynaud’s discomfort, pain, sleep and wound problems often improve once addressed directly. Others take longer: skin softening and stabilisation of lung function are measured over months and depend on consistent follow-up. Patients are encouraged to stay active within safe limits, protect hands and feet from cold, keep skin supple, follow medication monitoring instructions and report new symptoms to their treating team promptly. Progress is not a straight line for everyone; flares, medication adjustments and new findings can occur. A clear plan tells you which changes are expected, which need review, and how your monitoring schedule will respond.

Why Acting Early Matters

Early and accurate assessment matters in scleroderma because several complications are far more manageable when identified before they advance. Raynaud’s phenomenon can progress to digital ulcers when circulation is poor. Reflux and swallowing problems can undermine nutrition, sleep, dental health and lung safety. Interstitial lung disease often develops gradually, and breathlessness may not be noticed until lung function has already changed measurably.

Pulmonary hypertension is another reason regular screening exists. It may begin as subtle fatigue or reduced exercise tolerance, and it is easily dismissed as deconditioning or ageing. Kidney crisis, though it affects only a minority of patients, is serious and turns on rapid recognition of rising blood pressure and changing kidney function — recognition that scheduled monitoring makes possible.

Delaying evaluation allows preventable damage to accumulate, and it tends to produce fragmented care, with each symptom treated separately by a different doctor instead of understood as one autoimmune disease. Acting early does not mean every patient needs aggressive therapy. It means the right level of monitoring and treatment can be chosen from objective findings and personal risk, rather than from guesswork.

Is scleroderma fatal or life threatening?

Scleroderma can be life threatening when it significantly affects the lungs, heart or kidneys, but the outlook varies enormously between individuals — this is not a diagnosis with a single trajectory. Localised scleroderma does not carry the internal organ risks of systemic disease at all. Within systemic sclerosis, many people with limited disease live for decades with manageable symptoms, while diffuse, rapidly progressive disease requires closer attention precisely because serious complications are more likely there. The management of complications such as renal crisis and lung disease has advanced considerably over recent decades, and structured surveillance exists specifically to catch these problems while they can still be treated. No honest clinician will promise you a particular course; what they can promise is a plan proportionate to your actual findings.

Benefits of Scleroderma Treatment

The benefits of treatment depend on the type and activity of your scleroderma, but the aims are consistent: reduce symptoms, protect organs and support daily function.

Benefit	What It Means for You
Clearer diagnosis and disease classification	Knowing whether the disease is localised or systemic, limited or diffuse, and which organs are involved sets the right level of monitoring and treatment from the start.
Better control of circulation symptoms	Treatment for Raynaud’s phenomenon and digital ulcers can reduce pain, improve hand comfort and lower the risk of tissue injury.
Protection of lung, heart and kidney health	Structured screening can identify early changes and allow timely treatment or closer observation when internal organ involvement is detected.
Improved digestive comfort and nutrition	Managing reflux, swallowing problems, motility issues and intestinal symptoms can improve eating, sleep, energy and weight stability.
Preservation of movement and independence	Physical and occupational therapy, hand care and skin management help maintain flexibility, grip and daily function.
Personalised long-term plan	A coordinated plan sets out medication choices, monitoring intervals, warning signs, and how care continues between visits.

Recovery Timeline and Follow-Up Expectations

Every patient’s course is different, but the following timeline gives a general sense of how care unfolds once evaluation and treatment planning begin.

Time Period	What Patients Can Expect
Day 1	The first consultation focuses on history, examination, review of prior records, and planning the tests needed to define disease type and organ involvement.
First Week	Many patients complete blood tests, circulation assessment, lung and heart screening, imaging or gastrointestinal evaluation. Initial symptom-focused treatment may begin.
First Month	The care team reviews results, confirms treatment priorities, adjusts medication, and explains monitoring requirements and warning signs.
First 3 to 6 Months	Medication response and side effects are assessed. Repeat blood tests or organ function tests evaluate stability or progression.
Longer Term	Ongoing follow-up focuses on maintaining function, detecting complications early, adjusting therapy as the disease changes, and coordinating care with local physicians.

Factors That Influence Outcomes

Outcomes in scleroderma depend on many factors: disease subtype, speed of progression, antibody profile, extent of skin involvement, presence of lung or heart disease, kidney risk, age, other medical conditions, smoking status, medication tolerance, and — not least — access to consistent follow-up. Two patients with the same diagnosis may need entirely different strategies, and comparing your course to someone else’s is rarely informative.

A good result usually means the disease has been accurately classified, active problems are treated, organ complications are detected early, and you hold a practical plan for daily life and long-term monitoring. For some patients the priority is symptom relief and mobility; for others it is stabilising lung function, preventing digital ulcers, controlling reflux or reducing kidney risk. The plan should reflect your priorities as well as your test results.

Medication adherence and safety monitoring matter throughout. Some immune-modulating treatments require regular blood tests and sensible infection precautions. Vascular medication may need dose adjustment in response to blood pressure, headaches or swelling. Gastrointestinal treatment tends to evolve as symptoms change. Patients who understand why each treatment is being used are consistently better placed to continue care safely — which is why a good clinic explains its reasoning rather than simply issuing prescriptions. Any adjustment, in either direction, belongs to your treating doctor.

Lifestyle measures cannot replace medical treatment when organ involvement is present, but they support outcomes meaningfully: avoiding tobacco, protecting hands and feet from cold, keeping skin moisturised, exercising within tolerance, following reflux precautions, keeping vaccinations up to date when appropriate, and attending to ulcers or infections early rather than late.

Finally, coordination among specialists shapes outcomes as much as any single decision. Scleroderma can require rheumatology, pulmonology, cardiology, nephrology, dermatology, gastroenterology, rehabilitation medicine, wound care, nutrition and sometimes psychology or pain management. When these perspectives are aligned, decisions are more coherent and the burden on you is smaller — fewer contradictory instructions, fewer repeated tests, one plan instead of six.

How Acibadem Organises Scleroderma Care

At Acibadem, scleroderma care is organised as a rheumatology-led programme with structured collaboration across the related departments. When lung, heart, kidney, skin or digestive involvement is suspected, the relevant specialists are brought into the assessment rather than left for the patient to find separately. For complex cases — significant lung disease, suspected pulmonary hypertension, kidney risk, severe skin progression, difficult gastrointestinal involvement, or genuine diagnostic uncertainty — multidisciplinary discussion is used so that treatment decisions are made from the whole picture, not from one department’s slice of it.

Diagnostic work covers the systems scleroderma most often affects: detailed autoimmune laboratory testing, nailfold capillary assessment, pulmonary function testing, high-resolution chest imaging, echocardiographic screening, gastrointestinal evaluation and organ-specific monitoring. The aim is to establish the current disease burden and a clear baseline for future comparison — because in a chronic disease, the trend often matters more than any single result.

Experience matters here because scleroderma treatment is a matter of judgement as much as protocol. Some patients need careful observation rather than escalation; others need early vascular or immune-directed therapy to reduce the risk of progression. The decision rests on patterns across symptoms, examination, antibodies, imaging, lung function, heart assessment, kidney tests and the patient’s own goals. A personalised plan protects you from both under-treatment and unnecessary treatment intensity.

The end product of the visit is designed to be usable. You should leave knowing what diagnosis has been made, which organs have been evaluated, what treatment is recommended and why, which side effects to watch for, when monitoring should be repeated, and which symptoms should prompt a review with your treating team. When appropriate, reports are prepared so the physicians who share your care can continue long-term monitoring without interruption or repetition.

Approaching Scleroderma With a Clear Plan

Scleroderma is a complex disease, but it does not have to be approached with uncertainty. A careful evaluation can establish which type of scleroderma you have, whether internal organs are involved, and what level of treatment and monitoring is proportionate to your actual findings — no more and no less.

Second opinions are common and entirely reasonable in complex autoimmune disease, particularly after a new diagnosis, when symptoms are changing, or when a current treatment plan has never been fully explained. Whatever path you take, the measure of a good evaluation is simple: you should come away understanding your disease, your plan and your monitoring schedule well enough to explain all three in your own words.